Drugs for Oral Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 57)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Cisplatin |
Approved |
Phase 2, Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
2 |
|
Docetaxel |
Approved, Investigational |
Phase 2, Phase 3 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
3 |
|
Fluorouracil |
Approved |
Phase 2, Phase 3 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
4 |
|
Melatonin |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
73-31-4 |
896 |
Synonyms:
[<sup>3</sup>H]-melatonin|[<sup>3</sup>H]MLT
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} acetamide
3-(2-Acetamidoethyl)-5-methoxyindole
5-Methoxy-N-acetyltryptamine
BCI-049
Circadin
Circadin®|MLT
GENERAL NUTRIT
HEALTH AID
HEIDADOUPPI
ICENIA
J5.258B
LIFE EXT
MELAPURE
Melatol
Melatonin
Melatonin (synth.) standard-grade
Melatonin (synth.) ultra-pure
Melatonina
Melatonine
Mélatonine
Melovine
MLT
|
MT6
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-acetamide
N-Acetyl-5-methoxytryptamine
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine melatonine
NATROL
NATURE'S BLEND
NATURES BOUNTY
NSC-113928
NSC-56423
QUALITY HEALTH
Regulin
S.GARD
TRAVELAG
VESPRO
VYTALONIN
|
|
5 |
|
Antioxidants |
|
Phase 3 |
|
|
|
6 |
|
Protective Agents |
|
Phase 3 |
|
|
|
7 |
|
Antimetabolites |
|
Phase 2, Phase 3 |
|
|
|
8 |
|
Immunosuppressive Agents |
|
Phase 2, Phase 3 |
|
|
|
9 |
|
Immunologic Factors |
|
Phase 2, Phase 3 |
|
|
|
10 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
11 |
|
Cetuximab |
Approved |
Phase 2 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
12 |
|
Raspberry |
Approved |
Phase 1, Phase 2 |
|
|
|
13 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
14 |
|
Olaparib |
Approved |
Phase 1, Phase 2 |
|
763113-22-0 |
23725625 |
Synonyms:
1-(CYCLOPROPYLCARBONYL)-4-[5-[(3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL]-2-FLUOROBENZOYL]PIPERAZINE
4-(3-{[4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL]CARBONYL}-4-FLUOROBENZYL)PHTHALAZIN-1(2H)-ONE
AZ2281
AZ-2281
AZD2281
AZD-2281
AZD-2281|AZD2281|Lynparza®
|
KEYLYNK-010 COMPONENT OLAPARIB
KU-0059436
KU59436
KU-59436
Lynparza
OLAPARIB
OLAPARIB COMPONENT OF KEYLYNK-010
|
|
15 |
|
Celecoxib |
Approved, Investigational |
Phase 2 |
|
169590-42-5 |
2662 |
Synonyms:
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENE-1-SULFONAMIDE
4-[5-(4-METHYLPHENYL)-3-TRIFLUOROMETHYL)-1H-PYRAZOL-YL]BENZENESULFONAMIDE
CELEBRA
Celebrex
CELECOX
Celecox®|Elyxyb® (DFN-15; oral solution)|Onsenal®|SC-58635|SC58635
Celecoxib
Célécoxib
|
Celecoxibum
Celocoxib
DFN15
DFN-15
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
SC-58635
|
|
16 |
|
Erlotinib |
Approved, Investigational |
Phase 2 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
17 |
|
Nimotuzumab |
Investigational |
Phase 2 |
|
780758-10-3 |
|
Synonyms:
HR3
NIMOTUZUMAB
THERACIM-HR3
|
THERALOC
THERALOC THERACIM
|
|
18 |
|
Antimitotic Agents |
|
Phase 2 |
|
|
|
19 |
|
Tubulin Modulators |
|
Phase 2 |
|
|
|
20 |
|
Albumin-Bound Paclitaxel |
|
Phase 2 |
|
|
|
21 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
22 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
23 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
24 |
|
Antibodies |
|
Phase 2 |
|
|
|
25 |
|
Poly(ADP-ribose) Polymerase Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
26 |
|
Pharmaceutical Solutions |
|
Phase 1, Phase 2 |
|
|
|
27 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
28 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
29 |
|
Cyclooxygenase Inhibitors |
|
Phase 2 |
|
|
|
30 |
|
Cyclooxygenase 2 Inhibitors |
|
Phase 2 |
|
|
|
31 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 2 |
|
|
|
32 |
|
Analgesics, Non-Narcotic |
|
Phase 2 |
|
|
|
33 |
|
Anti-Inflammatory Agents |
|
Phase 2 |
|
|
|
34 |
|
Analgesics |
|
Phase 2 |
|
|
|
35 |
|
Mitogens |
|
Phase 2 |
|
|
|
36 |
|
Rivoceranib |
Investigational |
Phase 1 |
|
811803-05-1 |
11315474 |
Synonyms:
APATINIB
apatinib (in China)|YN968D1
Apatinib mesylate
Rivoceranib
|
Rivoceranib mesylate
YN968D1
YN968D1 free base
|
|
37 |
|
Immune Checkpoint Inhibitors |
|
Phase 1 |
|
|
|
38 |
|
Carbamide peroxide |
Approved |
|
|
124-43-6 |
|
Synonyms:
Carbamide peroxide
Hydrogen peroxide carbamide
Urea dioxide
|
Urea hydrogen peroxide
Urea peroxide
|
|
39 |
|
Licorice |
Approved |
Early Phase 1 |
|
|
|
Synonyms:
|
40 |
|
Phenol |
Approved, Experimental |
Early Phase 1 |
|
108-95-2 |
996 |
Synonyms:
ACIDE CARBOLIQUE
ACIDE PHENIQUE
Acide phénique
ANBESOL
BENZENOL
BENZOPHENOL
CAMPHO-PHENIQUE COLD SORE GEL
CAMPHO-PHENIQUE GEL
CAMPHO-PHENIQUE LIQUID
Carbol
Carbolate
CARBOLIC ACID
CARBOLIC ACID LIQUID
CARBOLIC OIL
CARBOLICUM ACIDUM
CARBOLSAEURE
CARBOLSAURE
Carbolsäure
CEPASTAT LOZENGES
CHLORASEPTIC
CUTICURA PAIN RELIEVING OINTMENT
ENT-1814
FENOL
FENOLO
FENOSMOLIN
FENOSMOLINE
HYDROXYBENZENE
HYDROXY-BENZENE
IPH
IZAL
KARBOLSAEURE
Karbolsäure
LIQUEFIED PHENOL
LIQUID PHENOL
LIQUIFIED PHENOL
MONOHYDROXY BENZENE
MONOHYDROXYBENZENE
|
MONOPHENOL
NSC-36808
OXYBENZENE
PAOSCLE
Phenate
PHENIC
PHENIC ACID
PHENIC ALCOHOL
PHENOL
PHENOL ALCOHOL
Phenol for disinfection
PHENOL HOMOPOLYMER
PHENOL LIQUID
PHENOL MOLTEN
PHENOL POLYMER-BOUND
PHENOL SOLUTION
PHENOL SYNTHETIC
PHENOL, LIQUEFIED
Phenol, sodium salt
Phenolate sodium
Phenolate, sodium
PHENOLATED WATER
PHENOLATED WATER FOR DISINFECTION
PHENOLE
PHENOSMOLIN
PHENYL ALCOHOL
PHENYL HYDROXIDE
Phenylate
PHENYLIC ACID
PHENYLIC ALCOHOL
PHOH
S.B. WARD
SALICYLIC ACID RELATED COMPOUND C
Sodium phenolate
SYNTHETIC PHENOL
TEA POLYPHENOL
|
|
41 |
|
Capsaicin |
Approved |
|
|
404-86-4 |
1548943 |
Synonyms:
(e)8-Methyl-N-vanillyl-6-nonenamide
(e)-8-Methyl-N-vanillyl-6-nonenamide
(e)-8-Methyl-N-vanillyl-6-nonenamide(8CL)
8 Methyl N vanillyl 6 nonenamide
8-Methyl-N-vanillyl-6-nonenamide
Alacan brand OF capsaicin
ALGRX 4975
ALGRX-4975
Antiphlogistine rub a-535 capsaicin
Axsain
CAPSAICIN
Capsaicina
Capsaicine
Capsicum farmaya
Capsidol
Capsin
Capzasin
Carter horner brand OF capsaicin
Centrum brand OF capsaicin
e-Capsaicin
Elan brand OF capsaicin
epsilon-Capsaicin
FEMA NO. 3404
Flemming brand OF capsaicin
|
Gelcen
Isodecenoate
Isodecenoate vanillylamide
Isodecenoic acid
Isodecenoic acid vanillylamide
Katrum
Link brand OF capsaicin
Medicis brand OF capsaicin
N-(4-Hydroxy-3-methoxybenzyl)-8-methylnon-trans-6-enamide
NGX-1998
NGX-4010
NSC-56353
QUTENZA
Qutenza®
Smaller brand OF capsaicin
Styptysat
Thompson brand OF capsaicin
trans-8-Methyl-N-vanillyl-6-nonenamide
Transacin
Vinas brand OF capsaicin
Zacin
Zostrix
ZOSTRIX HP
|
|
42 |
|
Pembrolizumab |
Approved |
|
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
43 |
|
Dimenhydrinate |
Approved |
|
|
523-87-5 |
10660 |
Synonyms:
(O-BENZHYDRYL(DIMETHYLAMINO)ETHANOL) 8-CHLOROTHEOPHYLLINATE
1)
8-CHLORO-1,3-DIMETHYL-3,7-DIHYDRO-1H-PURINE-2,6-DIONE - 2-(DIPHENYLMETHOXY)-N,N-DIMETHYLETHANAMINE (1
8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
ANTEMIN
BENZHYDRYL-BETA-DIMETHYLAMINOETHYLETHER 8-CHLOROTHEOPHYLLINE
Benzhydryl-β-dimethylaminoethylether 8-chlorotheophylline
BETA-DIMETHYLAMINOETHYL BENZHYDRYL ETHER 1,3-DIMETHYL-8-CHLOROXANTHINE
CHLORANAUTINE
DIMENHIDRINATO
DIMENHYDRINATE
|
DIMENHYDRINATUM
DIPHENHYDRAMINE 8-CHLOROTHEOPHYLLINATE
DIPHENHYDRAMINE 8-CHLOROTHEOPHYLLINE
DIPHENHYDRAMINE THEOCLATE
DIPHENHYDRINATE
DRAMAMINE
N,N-DIMETHYL-2-DIPHENYLMETHOXYETHYLAMINE 8-CHLOROTHEOPHYLLINATE
NSC-117855
O-BENZHYDRYLDIMETHYLAMINOETHANOL 8-CHLOROTHEOPHYLLINATE
VERTIGO-VOMEX S
β-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
|
|
44 |
|
Arginine |
Approved, Investigational, Nutraceutical |
|
|
74-79-3 |
6322 |
Synonyms:
(2S)-2-Amino-5-(carbamimidamido)pentanoate
(2S)-2-Amino-5-(carbamimidamido)pentanoic acid
(2S)-2-AMINO-5-(DIAMINOMETHYLIDENEAMINO)PENTANOIC ACID
(2S)-2-AMINO-5-[(DIAMINOMETHYLIDENE)AMINO]PENTANOIC ACID
(2S)-2-Amino-5-guanidinopentanoate
(2S)-2-Amino-5-guanidinopentanoic acid
(2S)-2-AMINO-5-GUANIDINO-PENTANOIC ACID
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoic acid
(S)-2-Amino-5-guanidinopentanoate
(S)-2-Amino-5-guanidinopentanoic acid
(S)-2-Amino-5-guanidinovalerate
(S)-2-Amino-5-guanidinovaleric acid
2-Amino-5-guanidinovalerate
2-Amino-5-guanidinovaleric acid
5-[(Aminoiminomethyl)amino]-L-norvaline
Arg
Arginina
Arginine
|
Arginine hydrochloride
Arginine, L isomer
Arginine, L-isomer
DL Arginine acetate, monohydrate
DL-Arginine acetate, monohydrate
Hydrochloride, arginine
L Arginine
L-(+)-Arginine
L-a-Amino-D-guanidinovalerate
L-a-Amino-D-guanidinovaleric acid
L-alpha-Amino-delta-guanidinovalerate
L-alpha-Amino-delta-guanidinovaleric acid
L-Arg
L-Arginin
L-ARGININE
L-Isomer arginine
Monohydrate DL-arginine acetate
N5-(Aminoiminomethyl)-L-ornithine
NSC-206269
R
|
|
45 |
|
Phenethyl Isothiocyanate |
Investigational |
|
|
2257-09-2 |
16741 |
Synonyms:
(2-Isothiocyanatoethyl)benzene
(2-Isothiocyanatoethyl)benzene, 9ci
2-Phenylethyl isothiocyanate
2-Phenylethyl isothiocyanic acid
beta-Phenethyl isothiocyanate
beta-Phenethyl isothiocyanic acid
beta-Phenylethyl isothiocyanate
beta-Phenylethyl isothiocyanic acid
b-Phenethyl isothiocyanate
b-Phenethyl isothiocyanic acid
b-Phenylethyl isothiocyanate
b-Phenylethyl isothiocyanic acid
PEITC
|
PEITC compound
Phenethyl isothiocyanate
Phenethyl isothiocyanic acid
Phenethyl mustard oil
Phenethylisothiocyanate
Phenylaethylsenfoel
Phenylethyl isothiocyanate
Phenylethyl isothiocyanic acid
Β-phenethyl isothiocyanate
Β-phenethyl isothiocyanic acid
Β-phenylethyl isothiocyanate
Β-phenylethyl isothiocyanic acid
|
|
46 |
|
Antiviral Agents |
|
Early Phase 1 |
|
|
|
47 |
|
Anti-Bacterial Agents |
|
Early Phase 1 |
|
|
|
48 |
|
Antimalarials |
|
Early Phase 1 |
|
|
|
49 |
|
Anti-Infective Agents |
|
|
|
|
|
50 |
|
Complement System Proteins |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 64)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effect of Melatonin in Combination With Neoadjuvant Chemotherapy to HIF-1⍺, CD44, CD133, and miR-210 Expression and Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma (OSCC) |
Completed |
NCT04137627 |
Phase 3 |
Melatonin 20 MG Oral Capsule;Placebo oral capsule |
2 |
Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma |
Completed |
NCT01542931 |
Phase 2, Phase 3 |
TPF induction chemotherapy |
3 |
Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) |
Completed |
NCT00964977 |
Phase 3 |
|
4 |
Neoadjuvant Toripalimab and Albumin Paclitaxel /Cisplatin Versus Docetaxel/ Cisplatin/ 5-fluorouracil (TPF) on Pathological Response in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma |
Recruiting |
NCT05125055 |
Phase 2, Phase 3 |
Toripalimab (anti-programmed death-1 inhibitor);Albumin paclitaxel;Cisplatin;Docetaxel;5-Fluorouracil |
5 |
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer |
Recruiting |
NCT04333537 |
Phase 2, Phase 3 |
Imaging Agent |
6 |
Development of Novel Diagnostic Tools and Therapeutic Strategies for Oral Cancer |
Unknown status |
NCT02739204 |
Phase 2 |
Celecoxib |
7 |
Phase 1/2, Open-Label, Single-Arm Safety and Efficacy Dose-Finding, Systemic Exposure, and Device Technical Effects of PRV111 (Cisplatin Transmucosal System) in Subjects With Oral Squamous Cell Carcinoma |
Completed |
NCT03502148 |
Phase 1, Phase 2 |
PRV111 (Cisplatin Transmucosal System) |
8 |
A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC) |
Completed |
NCT00933387 |
Phase 2 |
Cetuximab,Paclitaxel,Cisplatin |
9 |
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention |
Completed |
NCT01192204 |
Phase 1, Phase 2 |
10% FBR containing bioadhesive gel;placebo gel |
10 |
Neoadjuvant Personalized Anti-PD-1 Therapy With Combination of Anti-VEGFR Therapy in Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Randomized Controlled Phase II Trial |
Recruiting |
NCT05069857 |
Phase 2 |
Camrelizumab (anti-PD-1 inhibitor);Apatinib (anti-VEGFR inhibitor) |
11 |
A Phase II, Prospective, Single-center, Randomized, Controlled Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma |
Recruiting |
NCT04367909 |
Phase 2 |
Nimotuzumab;Docetaxel;Carboplatin |
12 |
Phase II Trial of Sintilimab, an Anti-PD-1 Monoclonal Antibody, in Combination With Carboplatin and Nab-paclitaxel , as a Novel Neoadjuvant Pre-Surgical Therapy for Oral Cavity or Oropharyngeal Squamous Cell Carcinoma |
Recruiting |
NCT04718415 |
Phase 2 |
sintilimab, paclitaxel, carboplatin |
13 |
A Phase I/II Study of the Fluorescent PARP1 Binding Imaging Agent PARPi-FL in Patients With Oral Squamous Cell Carcinomas |
Recruiting |
NCT03085147 |
Phase 1, Phase 2 |
Olaparib |
14 |
Camrelizumab Plus Docetaxel and Cisplatin as First-line Therapy in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients(CHANCE): an Open-label, Single-arm, Phase II Trial |
Recruiting |
NCT05611463 |
Phase 2 |
Camrelizumab Plus Docetaxel and Cisplatin |
15 |
Phase II Trial of Sintilimab, an Anti-PD-1 Monoclonal Antibody, in Combination With Reduction of Cycles of Chemotherapy, as a Novel Neoadjuvant Pre-Surgical Therapy for Oral Cavity or Oropharyngeal Squamous Cell Carcinoma |
Recruiting |
NCT05098119 |
Phase 2 |
Sintilimab, Nab-paclitaxel, Carboplatin;Sintilimab |
16 |
GDF15 (Growth Differentiation Factor 15) Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at T3/T4cN0M0 Stage: a Phase II Randomized Controlled Trial |
Recruiting |
NCT02285530 |
Phase 2 |
TPF induction chemotherapy |
17 |
A Randomized Phase II Trial of TPF Induction Chemotherapy in cN2 Patients With Oral Squamous Cell Carcinoma |
Recruiting |
NCT02285543 |
Phase 2 |
TPF induction chemotherapy |
18 |
Cyclin D1 Based TPF(Docetaxel, Cisplatin and 5-fluorouracil) Induction Chemotherapy for OSCC(Oral Squamous Cell Carcinoma) Patients at cN2(Clinical Node 2) Stage: a Phase II Randomized Controlled Trial |
Recruiting |
NCT02290145 |
Phase 2 |
TPF group |
19 |
A Randomized Phase II Study of Neoadjuvant PD-1 Blockade Alone or Plus TPF Induction Chemotherapy for Resectable Local Advanced Oral Squamous Cell Carcinoma |
Active, not recruiting |
NCT04649476 |
Phase 2 |
Camrelizumab;Camrelizumanb plus TPF |
20 |
Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study. |
Active, not recruiting |
NCT02748707 |
Phase 2 |
Arm1;Arm 2;Arm 3 |
21 |
Phase I Trial Of Intratumoral EGFR Antisense DNA And DC-Chol Liposomes In Advanced Oral Squamous Cell Carcinoma |
Completed |
NCT00009841 |
Phase 1 |
DC-cholesterol liposome |
22 |
Safety and Efficacy Evaluation of Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (Non NPC): A Phase I Trial |
Active, not recruiting |
NCT04413214 |
Phase 1 |
Carrimycin |
23 |
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients: A Single-arm Phase I Trial |
Active, not recruiting |
NCT04473716 |
Phase 1 |
Toripalimab;Paclitaxcel;Cisplatin |
24 |
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Single-arm Phase I Trial |
Active, not recruiting |
NCT04393506 |
Phase 1 |
Camrelizumab;Apatinib |
25 |
Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma |
Unknown status |
NCT01987934 |
|
|
26 |
Validation of Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study |
Unknown status |
NCT03345966 |
|
|
27 |
The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw |
Unknown status |
NCT03418454 |
|
|
28 |
Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line |
Unknown status |
NCT03619304 |
|
|
29 |
Pivotal Validation Study of Salivary Biomarkers for the Risk Stratification of Patients With Lesions Suspicious for Oral Squamous Cell Carcinoma |
Unknown status |
NCT01587573 |
|
|
30 |
A Randomized, Double Blind, Controlled, Multi-center, Phase III Study to Assess Efficacy of Low Level Diode Laser (100 MW, 658 Nm), in the Prevention and Treatment of Radiochemotherapy-induced Mucositis in Head and Neck Cancer. |
Unknown status |
NCT01772706 |
|
|
31 |
Survival Benefit of Elective Neck Dissection for Patients With T1,2N0M0 Oral Squamous Cell Carcinoma-A Prospective Multicenter Randomized Controlled Study |
Unknown status |
NCT01334320 |
|
|
32 |
The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma |
Unknown status |
NCT01946230 |
|
|
33 |
Apoptotic and Anti-Proliferative Effects of Licorice Extract (Licochalcone A) and Paclitaxel Chemotherapy on Human Oral Squamous Cell Carcinoma Cell Line |
Unknown status |
NCT03292822 |
Early Phase 1 |
Paclitaxel |
34 |
The Role of microRNA-29b in the Oral Squamous Cell Carcinoma |
Unknown status |
NCT02009852 |
|
|
35 |
Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma |
Unknown status |
NCT03877159 |
|
|
36 |
Myeloid-derived Suppressor Cells (MDSCs) Detection Before and After Beta-glucan Administration in Oral Squamous Cell Carcinoma Patients |
Unknown status |
NCT04387682 |
|
|
37 |
SEND Trial The Role of Selective Neck Dissection Used Electively in Patients With Early Oral Squamous Cell Carcinoma (1-3cm Primary Size) and No Clinical Evidence of Lymph Node Metastases in the Neck |
Unknown status |
NCT00571883 |
|
|
38 |
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma |
Unknown status |
NCT00173849 |
|
|
39 |
Verification of Saliva MMP-1 as a Strong Diagnostic Marker of Oral Cavity Cancer |
Completed |
NCT05049408 |
|
|
40 |
Fluorescent Visualization in Early Oral Cancer |
Completed |
NCT02306967 |
|
|
41 |
Molecular Mechanisms of Precancerous and Cancerous Lesions of the Oral Cavity |
Completed |
NCT03026361 |
|
|
42 |
Toluidine Blue Versus Frozen Sections for Assessment of Tumor Margins in Oral Squamous Cell Carcinoma |
Completed |
NCT03554967 |
|
|
43 |
Oral Metal Contact Allergy: A Cause of Oral Squamous Cell Carcinoma? |
Completed |
NCT00693550 |
|
|
44 |
Modern Hybrid Imaging for Staging and Monitoring Patients With Oral Squamous Cell Carcinoma |
Completed |
NCT04280159 |
|
|
45 |
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma. (Retrospective-cohort Study) |
Completed |
NCT03109457 |
|
|
46 |
Salivary and Serum Levels of Chemerin and MMP-9 in Oral Precancer and Oral Squamous Cell Carcinoma. |
Completed |
NCT02323672 |
|
|
47 |
A Phase 1b Pilot Study Evaluating Oral Administration of Freeze-Dried Black Raspberries in Pre-Surgical Patients With Oral Squamous Cell Carcinoma |
Completed |
NCT01465776 |
|
|
48 |
Survival Analysis of Segmental Mandibulectomy With Immediate Vascularized Fibula Flap Reconstruction in Stage IV Oral Squamous Cell Carcinoma Patients |
Completed |
NCT04967638 |
|
|
49 |
A Double Blind, Randomised, Placebo Controlled, Feasibility Phase III Clinical Trial of Peri-operative Immune-enhancing Feed in Patients Undergoing Surgery for Advanced Head and Neck Cancer |
Completed |
NCT01314755 |
|
|
50 |
Ultrasound in Oral Tongue Cancer- Measurement of Depth of Invasion and Intraoperative Help in the Resection |
Completed |
NCT04059861 |
|
|
|